Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue SUPPL. C, 1996, Pages 115-124

  Laurent, K ^a  

^a Department of Gastroenterology   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; MACROLIDE; ROXITHROMYCIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; GASTRITIS; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; URTICARIA; VOMITING;

EID: 0029789257     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.suppl_c.115     Document Type: Article

References (22)

1. Balmes, P., Clerc, G., Dupont, B., Labram, C., Pariente, R. & Poirier, R. (1991). Comparative study of azithromycin and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infections. European Journal of Clinical Microbiology and Infectious Diseases 10, 437-9.
2. Blanc, F., D'Enfert, J., Fiessinger, S., Lenoir, A., Renault, M. & Rezvani, Y. (1987). An evaluation of tolerance of roxithromycin in adults. Journal of Antimicrobial Chemotherapy 20, Suppl. B, 179-83.
3. Bradbury, F. (1993). Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 31, Suppl E, 153-62.
4. Bright, G. M., Nagel, A. A., Bordner, J., Desai, K. A., Dibrino, J. N., Nowakowska, J. et al. (1988). Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives: a new class of macrolide antibiotics, the azalides. Journal of Antibiotics 41, 1029-47.
5. Chirgwin, K., Roblin, P. M. & Hammerschlag, M. R. (1989). In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). Antimicrobial Agents and Chemotherapy 33, 1634-5.
6. Daniel, R. & the European Azithromycin Study Group. (1991). Simplified treatment of acute lower respiratory tract infection with azithromycin: a comparison with erythromycin and amoxycillin. Journal of International Medical Research 19, 373-83.
7. Dark, D. (1991). Multicenter evaluation of azithromycin and cefaclor in lower respiratory tract infections. American Journal of Medicine 9, Suppl. 3A, 31-5.
8. Fiese, E. F. & Steffen, S. H. (1990). Comparison of The acid stability of azithromycin and erythromycin A. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 39-47.
9. Foulds, G., Shepard, R. M. & Johnson, J. B. (1990). The pharmacokinetics of azithromycin in human serum and tissues. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 73-82.
10. Girard, A. E., Girard, D., English, A. R., Gootz, T. D., Cimochowski, C. R., Faiella, J. A. et al. (1987). Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrobial Agents and Chemotherapy 31, 1948-54.
11. Gladue, R. P., Bright, G. M., Isaacson, R. E. & Newborg, M. F. (1989). In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrobial Agents and Chemotherapy 33, 277-82.
12. Goldstein, F. W., Kitzis, M. D., Miegi, M. & Acar, J. F. (1990). In-vitro activity of azithromycin against various Gram-negative bacilli and anaerobic bacteria. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 15-8.
13. Hardy, D. J., Hensey, D. M., Beyer, J. M., Vojtko, C., McDonald, E. J. & Fernandes, P. R. (1988). Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrobial Agents and Chemotherapy 32, 1710-9.
14. Hoepelman, A. I. M., Sips, A. P., van Helmond, J. L. M., van Barneveld, P. W. C., Neve, A. J., Zwinkels, M. et al. (1993). A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 31, Suppl. E, 147-52.
15. Hopkins, S. (1991). Clinical toleration and safety of azithromycin. American Journal of Medicine 91, Suppl. 3A, 40S-5.
16. Kinasewitz, G. & Wood, R. G. (1991). Azithromycin versus cefaclor treatment of acute bacterial pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 10, 872-7.
17. Laufen, H., Wildfeuer, A. & Lach, P. (1990). Mechanism of azithromycin uptake in human polymorphonuclear leucocytes. Arzneimittel-Forschung 40, 686-9.
18. Morris, D. L., De Souza, A., Jones, J. A. & Morgan, D. E. (1991). High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose. European Journal of Clinical Microbiology and Infectious Diseases 10, 859-61.
19. National Committee for Clinical Laboratory Standards. (1993). Minimal inhibitory concentration (MIC) interpretative standards (μg/ml) for organisms other than Haemophilus, Neisseria gonorrhoeae and Streptococcus pneumonias: Approved Standard M7-3. NCCLLS, Villanova, PA.
20. Retsema, J., Girard, A., Schelkly, W., Manousos, M., Anderson, M., Bright, G. et al. (1987). Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrobial Agents and Chemotherapy 31, 1939-47.
21. Rylander, M. & Hallander, H. O. (1988). In vitro comparison of the activity of doxycycline, tetracycline, erythromycin and a new macrolide, CP-62993, against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum. Scandinavian Journal of Infectious Diseases Suppl. 53, 12-7.
22. Wildfeuer, A., Laufen, H., Müller-Wenning, D. & Haferkamp, O. (1989). Interaction of azithromycin and human phagocytic cells. Uptake of the antibiotic and the effect on the survival of ingested bacteria in phagocytes. Arzneimittel-Forschung 39, 755-8.